Similar Papers

Paper Title
Journal
Date
Author
PD05-02: Effect of HER2/Topoisomerase II alpha (TOP2A) Gene Status or Protein Expression and Chromosome 17 (CEP17) Polysomy on the Outcome of Breast Cancer Patients Treated with Anthracycline-Containing Dose-Dense Sequential Adjuvant Chemotherapy with or without Paclitaxel – A Pooled Analysis of Two Hellenic Cooperative Oncology Group (HeCOG) Phase III Trials.
U Dafni ... E Tsolaki
Cancer Research | VOL. 71
U Dafni, et. al.U Dafni ... E Tsolaki
15 Dec 2011
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial
...
Cancer Chemotherapy and Pharmacology | VOL. 69
, et. al. ...
08 Sep 2011
Abstract P3-09-07: Prognostic value of immunophenotypically defined subtypes in patients treated with dose-dense sequential adjuvant chemotherapy in the trastuzumab era. A Hellenic Cooperative Oncology Group study
George Fountzilas ... Olympia Tzaida
Cancer Research | VOL. 75
George Fountzilas, et. al.George Fountzilas ... Olympia Tzaida
30 Apr 2015
Evaluation of the prognostic/predictive value of HER2/TOP2A gene amplification and protein overexpression in patients with high-risk breast cancer treated with dose-dense sequential adjuvant chemotherapy.
O Tzaida ... M Bobos
Journal of Clinical Oncology | VOL. 29
O Tzaida, et. al.O Tzaida ... M Bobos
20 May 2011
View more papers

More From: European Journal of Cancer

Paper Title
Journal
Date
Author
Editorial Board
-
European Journal of Cancer | VOL. 216
--
01 Feb 2025
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial
Guilhem Roubaud ... Karim Fizazi
European Journal of Cancer | VOL. -
Guilhem Roubaud, et. al.Guilhem Roubaud ... Karim Fizazi
01 Feb 2025
Editorial Board
-
European Journal of Cancer | VOL. 217
--
01 Feb 2025
Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine
Karin P.S Langenberg ... Jan J Molenaar
European Journal of Cancer | VOL. -
Karin P.S Langenberg, et. al.Karin P.S Langenberg ... Jan J Molenaar
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.